Clinical trial

Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)

NCT03648554

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2019-09-01

PhasePHASE4

Study timeline

Study start (estimated)2019-09-01Date precision: day

Registry last updated2019-06-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 2unresolved

NASH - Nonalcoholic Steatohepatitisunresolved

Interventions

dulaglutide (TRULICITY®) 1.5 mgDRUG

reinforced dietary monitoringOTHER

Sponsors & collaborators

Central Hospital, Nancy, Francelead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

ToulouseFrance1 MarseilleFrance1 MontpellierFrance1 DijonFrance1 CaenFrance1 RouenFrance1 ReimsFrance1 Vandœuvre-lès-NancyFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03648554 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.